Federman & Sherwood Investigates HALO Branded Solutions for Data Breach
Federman & Sherwood Investigates HALO Branded Solutions for Data Breach
The law firm of Federman & Sherwood has initiated an investigation into HALO Branded Solutions with respect to their recent data breach. In November 2023, HALO’s computer systems within their network were accessed by a sophisticated threat actor using techniques to evade detection by their information security defenses. They recently learned that a criminal threat actor had access to computer systems containing personal information and was able to acquire those files. The personal information that was accessed in the incident included the following: individuals’ name, date of birth and Social Security number.
If you wish to discuss this action, obtain further information, and/or participate in this litigation, please contact Tiffany Peintner either by email at trp@federmanlaw.com or visit our firm’s website www.federmanlaw.com.
Tiffany Peintner
FEDERMAN & SHERWOOD
trp@federmanlaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402192818/en/
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track